{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:42:16Z","timestamp":1792244536758,"version":"4.4.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,17]]},"DOI":"10.7759\/cureus.118057","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:59:04Z","timestamp":1792241944000},"source":"Crossref","is-referenced-by-count":0,"title":["Cannabidiol (CBD) for Pain: A Narrative Review of Evidence to Date"],"prefix":"10.7759","author":[{"given":"Robert B","family":"Raffa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph V","family":"Pergolizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Breve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Vortsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah N","family":"EL-Tallawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228870","article-title":"Cannabidiol for pain treatment: focus on pharmacology and mechanism of action","volume":"21","author":"Mlost J","year":"2020","unstructured":"Mlost J, Bryk M, Starowicz K. Cannabidiol for pain treatment: focus on pharmacology and mechanism of action. Int J Mol Sci. 2020, 21:10.3390\/ijms21228870","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-13284-0","article-title":"FABP5 deletion in nociceptors augments endocannabinoid signaling and suppresses TRPV1 sensitization and inflammatory pain","volume":"12","author":"Bogdan DM","year":"2022","unstructured":"Bogdan DM, Studholme K, DiBua A, et al.. FABP5 deletion in nociceptors augments endocannabinoid signaling and suppresses TRPV1 sensitization and inflammatory pain. Sci Rep. 2022, 12:9241. 10.1038\/s41598-022-13284-0","journal-title":"Sci Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2021.108712","article-title":"Cannabidiol effectively reverses mechanical and thermal allodynia, hyperalgesia, and anxious behaviors in a neuropathic pain model: possible role of CB1 and TRPV1 receptors","volume":"197","author":"Silva-Cardoso GK","year":"2021","unstructured":"Silva-Cardoso GK, Lazarini-Lopes W, Hallak JE, Crippa JA, Zuardi AW, Garcia-Cairasco N, Leite-Panissi CR. Cannabidiol effectively reverses mechanical and thermal allodynia, hyperalgesia, and anxious behaviors in a neuropathic pain model: possible role of CB1 and TRPV1 receptors. Neuropharmacology. 2021, 197:108712. 10.1016\/j.neuropharm.2021.108712","journal-title":"Neuropharmacology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231710016","article-title":"TRPV1: a common denominator mediating antinociceptive and antiemetic effects of cannabinoids","volume":"23","author":"Louis-Gray K","year":"2022","unstructured":"Louis-Gray K, Tupal S, Premkumar LS. TRPV1: a common denominator mediating antinociceptive and antiemetic effects of cannabinoids. Int J Mol Sci. 2022, 23:10.3390\/ijms231710016","journal-title":"Int J Mol Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01365","article-title":"A systematic review on the pharmacokinetics of cannabidiol in humans","volume":"9","author":"Millar SA","year":"2018","unstructured":"Millar SA, Stone NL, Yates AS, O'Sullivan SE. A systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol. 2018, 9:1365. 10.3389\/fphar.2018.01365","journal-title":"Front Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1089\/can.2023.0025","article-title":"Pharmacokinetics of cannabidiol: a systematic review and meta-regression analysis","volume":"9","author":"Moazen-Zadeh E","year":"2024","unstructured":"Moazen-Zadeh E, Chisholm A, Bachi K, Hurd YL. Pharmacokinetics of cannabidiol: a systematic review and meta-regression analysis. Cannabis Cannabinoid Res. 2024, 9:939-66. 10.1089\/can.2023.0025","journal-title":"Cannabis Cannabinoid Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2174\/1389201020666191202111534","article-title":"The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities","volume":"21","author":"Xu DH","year":"2020","unstructured":"Xu DH, Cullen BD, Tang M, Fang Y. The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities. Curr Pharm Biotechnol. 2020, 21:390-402. 10.2174\/1389201020666191202111534","journal-title":"Curr Pharm Biotechnol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s42238-025-00312-9","article-title":"Randomized single-dose crossover comparative bioavailability study of two novel oral cannabidiol (CBD) formulations in healthy volunteers under fed conditions, compared to a standard CBD isolate capsule","volume":"7","author":"Pisak MN","year":"2025","unstructured":"Pisak MN, Bereket E, Erenmemisoglu A. Randomized single-dose crossover comparative bioavailability study of two novel oral cannabidiol (CBD) formulations in healthy volunteers under fed conditions, compared to a standard CBD isolate capsule. J Cannabis Res. 2025, 7:54. 10.1186\/s42238-025-00312-9","journal-title":"J Cannabis Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/ph17020244","article-title":"Strategies to improve cannabidiol bioavailability and drug delivery","volume":"17","author":"O'Sullivan SE","year":"2024","unstructured":"O'Sullivan SE, Jensen SS, Kolli AR, Nikolajsen GN, Bruun HZ, Hoeng J. Strategies to improve cannabidiol bioavailability and drug delivery. Pharmaceuticals (Basel). 2024, 17:10.3390\/ph17020244","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100777","article-title":"Oral cannabidiol (CBD) as add-on to paracetamol for painful chronic osteoarthritis of the knee: a randomized, double-blind, placebo-controlled clinical trial","volume":"35","author":"Pramhas S","year":"2023","unstructured":"Pramhas S, Thalhammer T, Terner S, Pickelsberger D, Gleiss A, Sator S, Kress HG. Oral cannabidiol (CBD) as add-on to paracetamol for painful chronic osteoarthritis of the knee: a randomized, double-blind, placebo-controlled clinical trial. Lancet Reg Health Eur. 2023, 35:100777. 10.1016\/j.lanepe.2023.100777","journal-title":"Lancet Reg Health Eur"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000002466","article-title":"Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind, placebo-controlled trial","volume":"163","author":"Vela J","year":"2022","unstructured":"Vela J, Dreyer L, Petersen KK, Arendt-Nielsen L, Duch KS, Kristensen S. Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind, placebo-controlled trial. Pain. 2022, 163:1206-14. 10.1097\/j.pain.0000000000002466","journal-title":"Pain"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.07.008","article-title":"Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial","volume":"85","author":"Rasmussen MU","year":"2026","unstructured":"Rasmussen MU, Christensen R, W\u00e6hrens EE, Henriksen M, Duhn PH, Bliddal H, Amris K. Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial. Ann Rheum Dis. 2026, 85:566-74. 10.1016\/j.ard.2025.07.008","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.51014","article-title":"The CANBACK trial: a randomised, controlled clinical trial of oral cannabidiol for people presenting to the emergency department with acute low back pain","volume":"214","author":"Bebee B","year":"2021","unstructured":"Bebee B, Taylor DM, Bourke E, Pollack K, Foster L, Ching M, Wong A. The CANBACK trial: a randomised, controlled clinical trial of oral cannabidiol for people presenting to the emergency department with acute low back pain. Med J Aust. 2021, 214:370-5. 10.5694\/mja2.51014","journal-title":"Med J Aust"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/03635465221109573","article-title":"Buccally absorbed cannabidiol shows significantly superior pain control and improved satisfaction immediately after arthroscopic rotator cuff repair: A placebo-controlled, double-blinded, randomized trial","volume":"50","author":"Alaia MJ","year":"2022","unstructured":"Alaia MJ, Hurley ET, Vasavada K, et al.. Buccally absorbed cannabidiol shows significantly superior pain control and improved satisfaction immediately after arthroscopic rotator cuff repair: A placebo-controlled, double-blinded, randomized trial. Am J Sports Med. 2022, 50:3056-63. 10.1177\/03635465221109573","journal-title":"Am J Sports Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/23259671231222265","article-title":"Cannabidiol for postoperative pain control after arthroscopic rotator cuff repair demonstrates no deficits in patient-reported outcomes versus placebo: 1-year follow-up of a randomized controlled tri","volume":"12","author":"Alaia MJ","year":"2024","unstructured":"Alaia MJ, Li ZI, Chalem I, et al.. Cannabidiol for postoperative pain control after arthroscopic rotator cuff repair demonstrates no deficits in patient-reported outcomes versus placebo: 1-year follow-up of a randomized controlled tri. Orthop J Sports Med. 2024, 12:23259671231222265. 10.1177\/23259671231222265","journal-title":"Orthop J Sports Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13051417","article-title":"Cannabidiol intervention for muscular tension, pain, and sleep bruxism intensity - a randomized, double-blind clinical trial","volume":"13","author":"Walczy\u0144ska-Dragon K","year":"2024","unstructured":"Walczy\u0144ska-Dragon K, Kurek-G\u00f3recka A, Niemczyk W, et al.. Cannabidiol intervention for muscular tension, pain, and sleep bruxism intensity - a randomized, double-blind clinical trial. J Clin Med. 2024, 13:10.3390\/jcm13051417","journal-title":"J Clin Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.26913","article-title":"Efficacy, safety, and regulation of cannabidiol on chronic pain: a systematic review","volume":"14","author":"Villanueva MR","year":"2022","unstructured":"Villanueva MR, Joshaghani N, Villa N, et al.. Efficacy, safety, and regulation of cannabidiol on chronic pain: a systematic review. Cureus. 2022, 14:e26913. 10.7759\/cureus.26913","journal-title":"Cureus"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0267420","article-title":"Cannabinoids versus placebo for pain: a systematic review with meta-analysis and trial sequential analysis","volume":"18","author":"Barakji J","year":"2023","unstructured":"Barakji J, Korang SK, Feinberg J, Maagaard M, Mathiesen O, Gluud C, Jakobsen JC. Cannabinoids versus placebo for pain: a systematic review with meta-analysis and trial sequential analysis. PLoS One. 2023, 18:e0267420. 10.1371\/journal.pone.0267420","journal-title":"PLoS One"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02459-1","article-title":"Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications","volume":"20","author":"Bilbao A","year":"2022","unstructured":"Bilbao A, Spanagel R. Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. BMC Med. 2022, 20:259. 10.1186\/s12916-022-02459-1","journal-title":"BMC Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.70021","article-title":"Cannabinoids as a natural alternative for the management of neuropathic pain: a systematic review of randomized placebo-controlled trials","volume":"16","author":"Reechaye D","year":"2024","unstructured":"Reechaye D, Perrine AL, Jahajeeah Y, Dookhee F, Robinson J, Banerjee I. Cannabinoids as a natural alternative for the management of neuropathic pain: a systematic review of randomized placebo-controlled trials. Cureus. 2024, 16:e70021. 10.7759\/cureus.70021","journal-title":"Cureus"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2020.12.001","article-title":"Cannabidiol use for fibromyalgia: prevalence of use and perceptions of effectiveness in a large online survey","volume":"22","author":"Boehnke KF","year":"2021","unstructured":"Boehnke KF, Gagnier JJ, Matallana L, Williams DA. Cannabidiol use for fibromyalgia: prevalence of use and perceptions of effectiveness in a large online survey. J Pain. 2021, 22:556-66. 10.1016\/j.jpain.2020.12.001","journal-title":"J Pain"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.51025","article-title":"Lack of efficacy of cannabidiol for relieving back pain: time to re-set expectations?","volume":"214","author":"Hayes C","year":"2021","unstructured":"Hayes C, Martin JH. Lack of efficacy of cannabidiol for relieving back pain: time to re-set expectations?. Med J Aust. 2021, 214:360-1. 10.5694\/mja2.51025","journal-title":"Med J Aust"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13627","article-title":"Cannabidiol-associated hepatotoxicity: a systematic review and meta-analysis","volume":"293","author":"Lo LA","year":"2023","unstructured":"Lo LA, Christiansen A, Eadie L, et al.. Cannabidiol-associated hepatotoxicity: a systematic review and meta-analysis. J Intern Med. 2023, 293:724-52. 10.1111\/joim.13627","journal-title":"J Intern Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16730","article-title":"Clinical guidance for cannabidiol-associated hepatotoxicity: a narrative review","volume":"39","author":"Eadie L","year":"2024","unstructured":"Eadie L, Lo LA, Boivin M, Deol JK, MacCallum CA. Clinical guidance for cannabidiol-associated hepatotoxicity: a narrative review. J Gastroenterol Hepatol. 2024, 39:2522-32. 10.1111\/jgh.16730","journal-title":"J Gastroenterol Hepatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1089\/can.2015.0012","article-title":"Human metabolites of cannabidiol: a review on their formation, biological activity, and relevance in therapy","volume":"1","author":"Ujv\u00e1ry I","year":"2016","unstructured":"Ujv\u00e1ry I, Hanu\u0161 L. Human metabolites of cannabidiol: a review on their formation, biological activity, and relevance in therapy. Cannabis Cannabinoid Res. 2016, 1:90-101. 10.1089\/can.2015.0012","journal-title":"Cannabis Cannabinoid Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3389\/fpls.2019.00697","article-title":"Legal and regulatory issues governing cannabis and cannabis-derived products in the United States","volume":"10","author":"Mead A","year":"2019","unstructured":"Mead A. Legal and regulatory issues governing cannabis and cannabis-derived products in the United States. Front Plant Sci. 2019, 10:697. 10.3389\/fpls.2019.00697","journal-title":"Front Plant Sci"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.885655","article-title":"Medicinal cannabis prescribing in Australia: an analysis of trends over the first five years","volume":"13","author":"MacPhail SL","year":"2022","unstructured":"MacPhail SL, Bedoya-P\u00e9rez MA, Cohen R, Kotsirilos V, McGregor IS, Cairns EA. Medicinal cannabis prescribing in Australia: an analysis of trends over the first five years. Front Pharmacol. 2022, 13:885655. 10.3389\/fphar.2022.885655","journal-title":"Front Pharmacol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.16515.1","article-title":"Epidiolex as adjunct therapy for treatment of refractory epilepsy: a comprehensive review with a focus on adverse effects","volume":"8","author":"Sekar K","year":"2019","unstructured":"Sekar K, Pack A. Epidiolex as adjunct therapy for treatment of refractory epilepsy: a comprehensive review with a focus on adverse effects. F1000Res. 2019, 8:10.12688\/f1000research.16515.1","journal-title":"F1000Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.2002.tb05998.x","article-title":"Cannabidiol: an overview of some pharmacological aspects","volume":"42","author":"Mechoulam R","year":"2002","unstructured":"Mechoulam R, Parker LA, Gallily R. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol. 2002, 42:11S-9S. 10.1002\/j.1552-4604.2002.tb05998.x","journal-title":"J Clin Pharmacol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmn.2023.10.002","article-title":"Effectiveness of cannabidiol to manage chronic pain: a systematic review","volume":"25","author":"Mohammed SY","year":"2024","unstructured":"Mohammed SY, Leis K, Mercado RE, Castillo MM, Miranda KJ, Carandang RR. Effectiveness of cannabidiol to manage chronic pain: a systematic review. Pain Manag Nurs. 2024, 25:e76-86. 10.1016\/j.pmn.2023.10.002","journal-title":"Pain Manag Nurs"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2017.1354409","article-title":"Placebo effects of edible cannabis: reported intoxication effects at a 30-minute delay","volume":"49","author":"Loflin MJ","year":"2017","unstructured":"Loflin MJ, Earleywine M, Farmer S, Slavin M, Luba R, Bonn-Miller M. Placebo effects of edible cannabis: reported intoxication effects at a 30-minute delay. J Psychoactive Drugs. 2017, 49:393-7. 10.1080\/02791072.2017.1354409","journal-title":"J Psychoactive Drugs"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.565617","article-title":"Clinical trials of cannabidiol for substance use disorders: outcome measures, surrogate endpoints, and biomarkers","volume":"12","author":"Morel A","year":"2021","unstructured":"Morel A, Lebard P, Dereux A, et al.. Clinical trials of cannabidiol for substance use disorders: outcome measures, surrogate endpoints, and biomarkers. Front Psychiatry. 2021, 12:565617. 10.3389\/fpsyt.2021.565617","journal-title":"Front Psychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/530378-cannabidiol-cbd-for-pain-a-narrative-review-of-evidence-to-date","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:59:05Z","timestamp":1792241945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/530378-cannabidiol-cbd-for-pain-a-narrative-review-of-evidence-to-date"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,17]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.118057","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,17]]}}}